ESG401 as first-line treatment for unresectable recurrent or metastatic triple-negative breast cancer.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, open-label, multicenter Phase 3 comparison of ESG401 versus investigator's choice chemotherapy as first-line therapy for unresectable recurrent or metastatic triple-negative breast cancer. Eligible participants have histologically confirmed TNBC, at least one measurable lesion per RECIST v1.1, ECOG performance status 0–1, and no prior systemic therapy for advanced disease. The protocol includes specific PD-L1-related eligibility rules and allows common chemotherapy options (paclitaxel, nab-paclitaxel, capecitabine, eribulin, or carboplatin) as the comparator. Primary outcomes focus on treatment efficacy and safety measures typical for a Phase 3 oncology trial.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Males or females aged ≥ 18 years ;
2. Histologically and/or cytologically confirmed TNBC;
3. De novo metastatic or relapsed ≥ 6 months post completion of treatment with curative intent;
4. No prior systemic anti-cancer therapy for unresectable recurrent or metastatic disease;
5. Participants whose tumours are PD-L1-negative, or Participants whose tumours are PD-L1-positive and have relapsed after prior PD-1/PD-L1 inhibitor therapy for early-stage breast cancer, or comorbidities precluding PD-1/PD-L1 inhibitor therapy;
6. Eligible for the chemotherapy options listed as investigator's choice chemotherapy (paclitaxel, nab-paclitaxel, capecitabine, eribulin, or carboplatin) as assessed by the investigator;
7. At least one measurable lesion per RECIST v1.1;
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 with no worsening within 2 weeks prior to randomization;
9. A life expectancy of at least 12 weeks;
10. Adequate organ and bone marrow function.

Key Exclusion Criteria:

1. Use of any investigational anti-cancer drug within 28 days or 5 half-lives before the first investigational product administration.
2. Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1.
3. Prior topoisomerase I inhibitor therapy, including antibody-drug conjugate(ADC) therapy, or prior TROP2 targeted therapy.
4. New thromboembolic events, intestinal obstruction, gastrointestinal bleeding or perforation within 6 months.
5. Subjects with symptomatic or untreated CNS metastases, or those requiring ongoing treatment for CNS metastases.
6. Patients with Primary CNS malignancy, or patients with other malignancies within 3 years prior to the first dose.
7. Patients with uncontrollable systemic diseases.
8. Patients with gastrointestinal diseases (such as chronic gastritis, chronic enteritis or gastric ulcers), or with a previous history of severe or chronic diarrhea.
9. Subjects with clinically significant cardiovascular disease.
10. Human Immunodeficiency Virus (HIV) infection.
11. Active hepatitis B or hepatitis C.
12. Known immediate or delayed hypersensitivity reaction to irinotecan or other camptocampin derivatives such as topotecan or to have had grade≥3 gastrointestinal reactions associated with irinotecan, or allergies, or to any investigational drug or excipient ingredient.
13. Pregnant or lactating women.

Where it's running

• Cancer Institute and Hospital, Chinese Academy of Medical Sciences
  Beijing, China Recruiting

Study contacts

• Principal investigator: Fei Ma — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Study coordinator: Xiaoyan Xing, PhD
• Email: xingxiaoyan@escugen.com
• Phone: +86 21 5855 6098

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized chemoimmunotherapy for early TNBC with high TILs (no anthracyclines upfront)

  This trial tests a 12-week, anthracycline-free neoadjuvant regimen of carboplatin, paclitaxel, and pembrolizumab in early-stage TNBC with high TILs to see if surgery outcomes are as good as historical regimens.

  Recruiting Phase 2 Medical University of South Carolina · Syracuse, New York and 1 other locations · NCT07743190

• BL-B01D1 plus PD-1 therapy vs nab-paclitaxel plus PD-1 therapy in untreated PD-L1-positive locally advanced or metastatic TNBC

  This phase 3 trial tests whether BL-B01D1 with a PD-1 antibody works better than nab-paclitaxel with a PD-1 antibody in women with newly treated, PD-L1-positive, locally advanced or metastatic triple-negative breast cancer.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07729956

• SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors

  This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.

  Recruiting at 3 sites Phase 1 SHY Therapeutics · Scottsdale, Arizona and 2 other locations · NCT07705334

• Isunakinra Plus Pembrolizumab Neoadjuvant Therapy for TNBC

  This trial tests whether adding isunakinra to pembrolizumab-based neoadjuvant chemotherapy can help treat newly diagnosed, locally advanced triple-negative breast cancer.

  Recruiting Phase 1/2 University Health Network, Toronto · Toronto, Ontario · NCT07698106

• Self-amplifying RNA vaccine ITI-5000 for stage 2-3 TNBC (two-part study)

  This Phase 1 trial tests ITI-5000, a saRNA cancer vaccine, in adults with stage 2-3 triple-negative breast cancer who finished standard treatment, to see if it’s safe and can provoke an immune response, alone or with approved immunotherapy.

  Recruiting at 4 sites Phase 1 Immunomic Therapeutics, Inc. · Los Angeles, California and 3 other locations · NCT07652242

• First-in-human imaging study of 68Ga-DFC413 and comparison with 68Ga-NNS309 in solid tumors

  This study tests a new radioactive imaging agent, 68Ga-DFC413, to see how it behaves in patients with several solid tumors and compares it to 68Ga-NNS309.

  Recruiting at 2 sites Phase 1 Novartis · Odense C and 1 other locations · NCT07630961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.